World Bispecific Antibody Summit, September 27–28, 2011, Boston, MA
暂无分享,去创建一个
[1] Hermann Einsele,et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] Guy Georges,et al. Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies , 2011, Proceedings of the National Academy of Sciences.
[3] D. Seimetz,et al. Humoral tumor-associated immune responses induced by catumaxomab in patients with malignant ascites. , 2011, Journal of Clinical Oncology.
[4] U. Brinkmann,et al. Bispecific digoxigenin-binding antibodies for targeted payload delivery , 2011, Proceedings of the National Academy of Sciences.
[5] P. Moore,et al. Application of dual affinity retargeting molecules to achieve optimal redirected T-cell killing of B-cell lymphoma. , 2011, Blood.
[6] R. Lerner,et al. Chemical generation of bispecific antibodies , 2010, Proceedings of the National Academy of Sciences.
[7] P. Moore,et al. Therapeutic control of B cell activation via recruitment of Fcgamma receptor IIb (CD32B) inhibitory function with a novel bispecific antibody scaffold. , 2010, Arthritis and rheumatism.
[8] P. Moore,et al. Effector cell recruitment with novel Fv-based dual-affinity re-targeting protein leads to potent tumor cytolysis and in vivo B-cell depletion. , 2010, Journal of molecular biology.
[9] M. Wittekind,et al. Enhancing Antibody Fc Heterodimer Formation through Electrostatic Steering Effects , 2010, The Journal of Biological Chemistry.
[10] J. Huston,et al. SEEDbodies: fusion proteins based on strand-exchange engineered domain (SEED) CH3 heterodimers in an Fc analogue platform for asymmetric binders or immunofusions and bispecific antibodies. , 2010, Protein engineering, design & selection : PEDS.
[11] D. Seimetz,et al. Catumaxomab , 2010, mAbs.
[12] P. Hoffmann,et al. Mode of cytotoxic action of T cell-engaging BiTE antibody MT110. , 2009, Immunobiology.
[13] J. Hess,et al. The trifunctional antibody ertumaxomab destroys tumor cells that express low levels of human epidermal growth factor receptor 2. , 2009, Cancer research.
[14] T. Barbui,et al. Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL). , 2009, Blood.
[15] F. Peale,et al. Variants of the Antibody Herceptin That Interact with HER2 and VEGF at the Antigen Binding Site , 2009, Science.
[16] T. Lebien,et al. B lymphocytes: how they develop and function. , 2008, Blood.
[17] H. Einsele,et al. Tumor Regression in Cancer Patients by Very Low Doses of a T Cell–Engaging Antibody , 2008, Science.
[18] S. Slavin,et al. Induction of long-lasting antitumor immunity by concomitant cell therapy with allogeneic lymphocytes and trifunctional bispecific antibody. , 2008, Experimental hematology.
[19] P. Parren,et al. Complement-dependent tumor cell lysis triggered by combinations of epidermal growth factor receptor antibodies. , 2008, Cancer research.
[20] I. Chaiken,et al. Enhanced EGFR inhibition and distinct epitope recognition by EGFR antagonistic MABS C225 and 425 , 2008, Cancer biology & therapy.
[21] P. Kufer,et al. The effect of dexamethasone on polyclonal T cell activation and redirected target cell lysis as induced by a CD19/CD3-bispecific single-chain antibody construct , 2007, Cancer Immunology, Immunotherapy.
[22] M. Kneba,et al. Molecular relapse in adult standard-risk ALL patients detected by prospective MRD monitoring during and after maintenance treatment: data from the GMALL 06/99 and 07/03 trials. , 2007, Blood.
[23] S. Slavin,et al. Use of trifunctional bispecific antibodies to prevent graft versus host disease induced by allogeneic lymphocytes. , 2006, Blood.
[24] P. Kufer,et al. Induction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cells. , 2006, Molecular immunology.
[25] P. Hoffmann,et al. Serial killing of tumor cells by cytotoxic T cells redirected with a CD19‐/CD3‐bispecific single‐chain antibody construct , 2005, International journal of cancer.
[26] M. Sliwkowski,et al. An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. , 2003, Molecular cell.
[27] P. Hoffmann,et al. Extremely potent, rapid and costimulation‐independent cytotoxic T‐cell response against lymphoma cells catalyzed by a single‐chain bispecific antibody , 2002, International journal of cancer.
[28] P. Ruf,et al. Induction of a long-lasting antitumor immunity by a trifunctional bispecific antibody. , 2001, Blood.
[29] R. Riesenberg,et al. Lysis of Prostate Carcinoma Cells by Trifunctional Bispecific Antibodies (αEpCAM × αCD3) , 2001 .
[30] B. Wollenberg,et al. The Fc-region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumour cells , 2000, British Journal of Cancer.
[31] B. Wollenberg,et al. Simultaneous activation of T cells and accessory cells by a new class of intact bispecific antibody results in efficient tumor cell killing. , 1999, Journal of immunology.
[32] L. Presta,et al. 'Knobs-into-holes' engineering of antibody CH3 domains for heavy chain heterodimerization. , 1996, Protein engineering.
[33] S. Thierfelder,et al. Preferential species-restricted heavy/light chain pairing in rat/mouse quadromas. Implications for a single-step purification of bispecific antibodies. , 1995, Journal of immunology.
[34] I. Pastan,et al. Preparation and characterization of a disulfide-stabilized Fv fragment of the anti-Tac antibody: comparison with its single-chain analog. , 1995, Molecular immunology.
[35] M. Bodmer,et al. Expression, purification and characterization of a mouse-human chimeric antibody and chimeric Fab' fragment. , 1992, The Biochemical journal.
[36] M. Tallman,et al. In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: fin , 2006, Blood.
[37] R. Riesenberg,et al. Lysis of prostate carcinoma cells by trifunctional bispecific antibodies (alpha EpCAM x alpha CD3). , 2001, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.